Bruce Booth, DPhil, Partner

Bruce Booth is a partner and focuses on novel biopharmaceutical products, therapeutic platforms, and innovative biomedical technologies.

Bruce has been instrumental in forming unique, innovative, and capital efficient structures for drug discovery and development. He co-founded miRagen Therapeutics and Nimbus Therapeutics, and served as acting chief executive officer of Nimbus while incubated at Atlas Venture’s offices. Bruce is chairman of Padlock Therapeutics, where he was a founding investor. Together with Peter Barrett, Bruce seeded and incubated Zafgen (NASDAQ: ZFGN), and identified and facilitated the successful in-licensing of the lead drug program. In addition to these companies, he currently serves as chairman of both Quartet Medicine and Rodin Therapeutics, and also serves on the boards of Lysosomal Therapeutics Inc. (LTI), Numerate, and Unum. Bruce was previously on the boards of past Atlas companies Avila Therapeutics (acquired by Celgene), Stromedix (acquired by Biogen), Prestwick (acquired by Biovail), and Proprius (acquired by Cypress Biosciences).

Prior to joining Atlas in 2005, Bruce was an investor with Caxton Health Holdings and before that, a consultant at McKinsey & Company, where he helped to build the Pharma R&D practice.

Bruce serves on UCB Pharma’s scientific advisory board as well as Pfizer’s Healthcare “R&D 2020″ Innovation Think Tank, and participates on several other advisory boards for academic medical centers. Bruce is also a trustee of the New York Academy of Medicine, where he serves on the executive committee as treasurer. He recently joined the Science Exchange’s Reproducibility Initiative Advisory Board, focused on improving the reliability of translational research.

Bruce blogs about life science venture capital topics at, which is also syndicated on Forbes. He has published numerous scientific papers and has authored various biotech venture capital review articles, including several in Nature Biotechnology. In 2010, Bruce was named to Boston Business Journal’s “40 under 40” list.

As a British Marshall Scholar, Bruce received a D.Phil. (PhD) in molecular immunology from Oxford University. His work focused on the study of HIV and tumor immune responses. He received a BS in biochemistry, summa cum laude, from The Pennsylvania State University.

Bruce enjoys fly fishing, skiing, snowboarding, and running. He lives in Wellesley, MA with his wife and three wonderful kids.